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Objective: To demonstrate a correlation of C-reactive protein levels with disease stage and
response to treatment in Hodgkin’s lymphoma patients of the Hematology Service of Santa
Casa  de São Paulo.
Methods: A retrospective study based on review of medical records was carried out of 38
patients diagnosed with Hodgkin’s lymphoma between October 2010 and December 2012.
Three patients met the exclusion criteria, giving a ﬁnal sample of 35 patients for analysis.
C-reactive protein levels >1 mg/dL were considered positive.
Results: Among the patients analyzed, median age was 29 years, 65% were male and 85%
had the classical nodular sclerosis subtype. Twenty-nine (82%) were in the advanced stage
and  28% had bulky mass at diagnosis. Seventeen percent had bone marrow invasion by lym-
phoma. Baseline C-reactive protein levels were associated with both stage (p-value = 0.0035)
and  presence or absence of B symptoms (p-value = 0.008). The highest C-reactive protein
levels were detected in patients with advanced disease while no patients with localized
disease had C-reactive protein >5 mg/dL (p-value = 0.02). After the ﬁrst treatment cycle, C-
reactive protein fell to near-normal levels and no direct association with response pattern
was  found. As the mean follow-up was only 14 months, it was not possible to determine
whether relapse was accompanied by a further increase in C-reactive protein.
Conclusion: Baseline C-reactive protein levels directly correlated with stage and presence or
absence of B symptoms, but the degree of improvement with treatment did not correlate
with response pattern. After a longer follow-up, it may be possible to assess whether relapse
correlates with a further increase in C-reactive protein levels.©  2015 Associac¸ão Brasileira de Hematologia, Hemoterapia e Terapia Celular. Publishedby Elsevier Editora Ltda. All rights reserved.
∗ Corresponding author at: Rua Alameda Joaquim Eugênio de Lima, 712, apt◦ 1111, Jardim Paulista, 01403-000 São Paulo, SP, Brazil.
E-mail  address: tasilveira6@yahoo.com.br (T.M.B. da Silveira da Rocha).
http://dx.doi.org/10.1016/j.bjhh.2015.05.003
1516-8484/© 2015 Associac¸ão Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier Editora Ltda. All rights
reserved.
er. 2 0
I
H
m
i
S
p
r
(
w
b
p
i
n
c
a
t
C
a
g
o
a
l
i
a
o
p
i
p
O
T
t
t
M
P
C
b
r
o
c
T
p
w
b
s
(
r
classical HL with the nodular sclerosis subtype and 11.5% had
the mixed cellularity subtype. Eighty-two percent of patients
were at an advanced stage and 28% had a bulky mass at
diagnosis. In addition, 17% had bone marrow invasion by the
lymphoma (Table 1). Median follow-up was 14 months.
Table 1 – Epidemiologic clinical data of patients.
Characteristic Number (n = 35)
Age – years (median) 29 years
Gender – n (%)
Male 22 (65)
Female 13 (35)
CRP – n (%)
<1 mg/dL 10 (28.5)
>1 mg/dL 25 (71.5)
Disease – n (%)
Localized 6 (18)
Advanced 29 (82)
B symptoms – n (%)
Present 23 (68)
Absent 12 (31)
Subtype – n (%)
Nodular sclerosis 30 (85.7)rev bras hematol hemot
ntroduction
odgkin’s lymphoma (HL) is a localized or disseminated
alignant lymphoproliferative disease which primarily
nvolves the lymph nodes, spleen, liver and bone marrow.
The estimated prevalence of HL for 2014 in the United
tates is 9190 new cases, accounting for 11.5% of all lym-
homas and 0.55% of all cancers diagnosed.1 The incidence
ate is 1.3–1.4:100,000.2
Discovered in 1930 by Tillet and Francis, C-reactive protein
CRP), as well as the erythrocyte sedimentation rate (ESR) a
ell established inﬂammatory marker used in a large num-
er of prognostic indicators for lymphoma, is an acute-phase
rotein induced by pro-inﬂammatory cytokines, in particular
nterleukin 6 (IL-6), but also interleukin 1 (IL-1) and tumor
ecrosis factor-alpha (TNF-),  and synthesized by hepato-
ytes. CRP is a nonspeciﬁc marker of inﬂammation. Generally,
n elevation in CRP occurs 4–6 h after the onset of inﬂamma-
ion, production doubles by eight hours and peaks at 36–50 h.
RP levels remain elevated during the inﬂammation process
nd drop sharply upon resolution.3
In addition, CRP has been used as a diagnostic and pro-
nostic marker for a number of neoplasms, particularly colon,
varian and breast cancer as well as hepatocellular carcinoma
nd other malignant diseases. A correlation between inter-
eukin 2 and CRP has been found in various neoplasms.4–6
In lymphomas, elevated CRP levels reﬂect the increase in
nﬂammatory cytokines, particularly IL-6, which are associ-
ted with malignant processes. IL-6 induces the production
f CRP by the liver and in HL patients, and this cytokine is
roduced by the cells of the lymphoma.7
In 1978, CRP was described as a biochemical marker of HL
n adults.8,9 Another study in 1985 showed elevated CRP in
atients with advanced HL.10
bjective
he objective of this study was to demonstrate the correla-
ion between CRP levels and disease stage and response to
reatment of HL patients.
ethods
atients diagnosed with HL and treated in the Outpatient
linic of the Hematology Service of Santa Casa de São Paulo
etween October 2010 and December 2012 were assessed.
The exclusion criteria were incomplete data in medical
ecords, and ﬁrst line treatment without response data at time
f analysis.
A retrospective analysis of clinical and laboratory data was
arried out by a single observer based on medical records.
he following data were collected: age at diagnosis, gender,
resence of bulky mass at diagnosis, disease stage (I and IIB
ithout bulky mass was deﬁned as initial stage and IIB with
ulky mass, III and IV as advanced stage), CRP at diagno-
is and after each cycle of chemotherapy, type of treatment
chemotherapy, radiotherapy) mid-treatment response (early),
esponse at end of treatment, and relapse. 1 5;3  7(4):242–246 243
In addition, possible adverse factors associated with ele-
vated CRP levels were assessed, such as infection during
treatment and the use of granulocyte-colony stimulating fac-
tor (G-CSF).
Response to treatment was assessed using the Cheson
criteria.11 No patient in this sample had been submitted to
positron emission tomography (PET).
The exams determining CRP levels were performed by
the central laboratory of the Faculdade de Ciências Médi-
cas da Santa Casa de São Paulo (FCMSCSP) one week before
the ﬁrst cycle of chemotherapy as part of the initial assess-
ment of the patient and repeatedly throughout treatment (one
week before each cycle of chemotherapy). CRP levels >1 mg/dL
were considered elevated. The CRP exam was performed by
the particle-enhanced immunoturbidimetric assay technique.
CRP agglutinates with latex particles coated with anti-CRP
monoclonal anti-bodies and the precipitate is determined tur-
bidimetrically.
Statistical analysis was performed using Pearson’s Chi-
square test and Student’s t-test. A p-value ≤ 0.05 was
considered statistically signiﬁcant. Data processing and sta-
tistical analyses were carried out using the statistical software
package SPSS version 15.0 for Windows.
Results
Of the 38 patients diagnosed with HL, three patients were
excluded due to missing data, giving a total of 35 patients for
analysis.
The median age was 29 years, 65% were male, 85.7% hadMixed cellularity 4 (11.5)
Rich in lymphocytes 1 (2.8)
Nodular lymphocyte-predominant 1 (2.8)
244  rev bras hematol hemoter.
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Figure 1 – Median C-reactive protein (CRP; mg/dL) at
baseline and after each cycle according to stage.
An assessment of the baseline CRP showed that the lev-
els were signiﬁcantly associated with disease stage. Mean
CRP in patients in the advanced stage of the disease was
7.85 ± 7.7 mg/dL whereas mean CRP in those with localized
disease was 1.21 ± 1.6 mg/dL (p-value = 0.0035). An analysis
was performed using a cut-off for CRP of 5 mg/dL. Under these
conditions, 50% of patients with advanced disease and no
cases with localized disease had CRP exceeding this level (p-
value = 0.02) (Figure 1).
On assessing the association between baseline CRP
levels and presence of B symptoms, the mean CRP in
patients without B symptoms was 2.18 ± 3.63 mg/dL versus
8.395 ± 7.97 mg/dL in patients presenting with B symptoms
(p-value = 0.008) (Figure 2). After the ﬁrst treatment cycle, the
association between CRP levels and patients with or without B
symptoms was no longer statistically signiﬁcant (1.435 mg/dL
versus 0.957 mg/dL; p-value = 0.412).
Assessment of the relationship between baseline CRP
and initial response revealed a mean baseline CRP of
5.2 ± 7.63 mg/dL in patients attaining full response (FR) at
mid-treatment and a mean of 7.6 ± 7.57 mg/dL in those
attaining a partial response (PR). However, these results were
not statistically signiﬁcant (p-value = 0.42). Using the cut-off
of 5 mg/dL for baseline CRP, 33% of patients attaining FR and
9
8
7
6
5
4
3
2
1
0
No: 12 patients Yes: 23 patients
Baseline CRP
No Yes
Figure 2 – B Symptoms and baseline C-reactive protein
level (CRP; mg/dL). 2 0 1 5;3  7(4):242–246
42% attaining PR had a baseline CRP ≥ 5 mg/dL, again without
statistical signiﬁcance (p-value = 0.46).
Assessment of response at end of treatment and CRP levels
at baseline revealed a mean of 5.69 ± 7.89 mg/dL in the group
attaining FR and 5.82 ± 7.22 mg/dL in the group attaining PR
(p-value = 0.49).
Considering the cut-off point of ≥5 mg/dL and ﬁnal
response, 27% of patients with FR and 55% of those with PR
had CRP ≥5 mg/dL (p-value = 0.16).
Thus, over half of the patients with PR at the end of treat-
ment had baseline CRP ≥ 5 mg/dL versus only 27% of those
attaining FR even though this was not statistically signiﬁcant.
Analysis of CRP levels after the ﬁrst chemotherapy cycle
(CRP1) identiﬁed no statistically signiﬁcant association with
stage, initial response or ﬁnal response.
With regard to stage, mean CRP1 was 1.52 ± 1.82 mg/dL for
cases with advanced disease and 0.61 ± 0.30 mg/dL in those
with localized disease (p-value = 0.245).
In relation to early response, the mean CRP1 of patients
attaining FR was 1.14 ± 1.56 mg/dL versus 1.37 ± 1.78 mg/dL for
those with PR (p-value = 0.75).
On analyzing the ﬁnal response, the mean CRP1
was 0.98 ± 1.31 mg/dL for the group attaining FR versus
2.3 ± 2.42 mg/dL for the group attaining PR (p-value = 0127).
Discussion
The characteristics of the patient sample of the present study
were similar to those reported in the literature; the median age
was 29 years, and they were predominantly male and with
the nodular sclerosis histological subtype. In contrast with
the international literature, the majority of our patients were
diagnosed in an advanced stage (82%). This may be explained
by difﬁculties accessing the Brazilian National Health Service
(SUS) and the slowness of the series of exams and procedures
the patient must undergo to reach the deﬁnitive diagnosis of
the neoplasm.
In the current study, an association was identiﬁed between
baseline CRP and the presence of B symptoms, with higher
baseline CRP levels in patients with B symptoms than
those without B symptoms (8.395 mg/dL × 2.18 mg/dL; p-
value = 0.008). This relationship was also found by Wieland
et al.12 in their study analyzing CRP in 95 children with HL, for
which the mean CRP level in patients with B symptoms was
8.0 mg/dL compared to 1.3 mg/dL (p-value < 0.001) in subjects
without B symptoms.
In addition, Zielinski et al.10 analyzed the acute-phase pro-
teins CRP, alpha 1-antitrypsin and alpha 1-glycoprotein acid
in 15 patients with advanced HL and found that all patients
with B symptoms at diagnosis also had higher CRP levels than
subjects without B symptoms (p-value < 0.02). This correlation
was also found in the current study.
One explanation for these ﬁndings is that B symptoms,
particularly fever, reﬂect greater tumor inﬂammatory activity.
In the present retrospective cohort, a relationship between
baseline CRP and disease stage was established. The highest
CRP levels were detected in those with advanced dis-
ease (mean baseline CRP: 7.85 ± 7.7 mg/dL; p-value = 0.0035)
(Figure 2). Also, when the cut-off point of 5 mg/dL was used,
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one of the patients with early stage disease had CRP levels
bove cut-off whereas half the patients in an advanced stage
ad CRP levels exceeding this value (p-value = 0.02). Similar
ndings were found by Child et al.9 in a vertical study in which
1% of patients with localized and 53% with advanced disease
xhibited high levels of this protein.
Zielinski et al.10 analyzed 15 patients with advanced HL
nd found elevated baseline CRP levels in all patients (mean
aseline CRP: 18.8 ± 5.8 mg/dL) and a signiﬁcant decline in lev-
ls after commencing treatment (p-value < 0.001). This latter
nding was also observed in the present analysis where, irre-
pective of stage, initial response or ﬁnal response, the level
f CRP fell sharply after commencing treatment.
In the present study, although a relationship between base-
ine CRP level and disease stage was initially established, CRP
eturned to normal or near-normal levels in all patients follow-
ng the ﬁrst cycle of chemotherapy. This most likely occurred
wing to a reduction in tumor inﬂammatory activity, but it
ad no direct correlation with the disappearance or otherwise
f the neoplasm. None of the patients with localized disease
ad baseline CRP levels exceeding 5 mg/dL and only 50% of
atients with advanced disease had CRP over 5 mg/dL. More-
ver, in the present study, eight patients (three with advanced
nd ﬁve with localized disease) had low baseline CRP levels, six
f which were below the detectable level. Of these six patients,
hree had advanced disease. This most probably compromised
he response assessment.
In this study, a sharp fall in CRP to levels under 2 mg/dL was
bserved within three chemotherapy cycles. Only one refrac-
ory patient failed to attain this level. The CRP concentration
n this patient fell to 3 mg/dL and then rose to over 5 mg/dL
ithout further decrease. Therefore, CRP may be analyzed as
 prognostic marker where treatment failure or the need for
herapeutic change is indicated when levels do not fall shortly
fter starting therapy.
In the analysis of the present cohort, the assessment of
aseline CRP and initial and ﬁnal response to treatment,
lthough not reaching statistical signiﬁcance, showed that
atients who  attained initial and ﬁnal PR had the highest
ean CRP levels at baseline, whereas those who attained FR
ad the lowest mean levels. The baseline CRP level therefore
ay serve as a predictor of treatment response. Patients with
ighest baseline CRP levels most likely have a more  advanced
tage of disease. This relationship was shown by the present
nvestigation and likewise by other studies.9,10 Thus, patients
ith higher baseline CRP are likely to have a poorer response to
reatment. Further comparative studies are needed to conﬁrm
his theory.
There are several limitations to using CRP as a progno-
tic factor in HL. CRP is an acute-phase protein and therefore
he predictive value of a single measurement should not be
onsidered in isolation but used in the context of a series of
easurements. This is true because other situations can also
ead to elevated CRP levels. One such situation is the use of
-CSF during treatment, which leads to an increase in the
RP protein both during and several days after discontinuing
se of the factor. This occurs because the medication leads
o an increase in the number of cytokines such as IL-6, IL-1
nd TNF-.13 CRP may also increase during infection. There-
ore, a multivariate analysis should be performed in an effort
1 1 5;3  7(4):242–246 245
to understand these confounding factors. This analysis was
not carried out in the present study and therefore it should be
seen as a limitation.
Our case series has several other limitations, such as the
small number of patients, the retrospective nature of the
analysis, and the large percentage of patients with advanced
disease and with B symptoms.
Even though this retrospective analysis did not show statis-
tical signiﬁcance between CRP levels and the initial and ﬁnal
responses obtained with treatment, it appears to be a promis-
ing prognostic marker. Given that the study had an average
follow-up of only 14 months, it was not possible to assess
CRP as a predictor of relapse. Further studies with longer
follow-ups are therefore required to verify this hypothesis. In
addition, a study involving multivariate analysis and compar-
ing CRP levels using PET is warranted in a bid to identify CRP
as a potential predictor of relapse and as a prognostic marker.
Conclusion
An association was found between elevated CRP levels and
both advanced disease and the presence of B symptoms in
this study. CRP was not a predictor of response or relapse.
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